ALGENICS Signs with ROQUETTE for the Development of an Innovative Microalgae Strain for High Value Industrial Uses

Share Article

ALGENICS SAS has announced that it has signed a new cooperation contract with the ROQUETTE Group for the development of an innovative microalgae strain capable of producing high levels of a metabolite for high value industrial uses.

ALGENICS SAS has announced that it has signed a new cooperation contract with the ROQUETTE Group for the development of an innovative microalgae strain capable of producing high levels of a metabolite for high value industrial uses. The two-year programme is based on the use of ALGENICS' genetic engineering platform, Algebiosys™, and is coupled with the signature of a licensing agreement for use of the technology. The financial terms of the contract have not been disclosed.

"We are delighted to be building on our relationship with the ROQUETTE Group to develop this strain. It will be soon highlighted on an industrial scale," explained Aude Carlier, CSO of ALGENICS. "The signature of this contract is a tangible example of the strong potential our technology offers for using microalgae in bioproduction," concluded Morgan Cabigliera, CEO of ALGENICS.

"We are particularly pleased to be embarking on this new project with ALGENICS. The strain that will be developed using Algebiosys™ technology will quickly help us to extend our range of nutraceuticals, cosmetics and pharmaceuticals derived from microalgae," commented Anne Cortier, Director of the NUTRAHUB® Nutrition and Health research programme at the Roquette Group.

About Algenics:

With its headquarters in Nantes (France), ALGENICS SAS is a marine biotechnology company focused on novel uses of eukaryotic microalgae as recombinant protein production system and oral drug delivery system. This spin-off from the French Research Institute for Exploitation of the Sea (Ifremer) has expertise in genetic engineering of microalgae, and exploits these "cellular factories" to fulfil the bioproduction requirements of pharmaceutical, cosmetic and nutraceutical industrials. Its patented technology, Algebiosys™, is marketed as a service offering and through licensing agreements. The company also develops orally delivered medicines to treat diseases in aquaculture populations. Its first product, Algevib fish™, is an antimicrobial peptide for treating vibrioses in farmed fish populations. Supported by Atlanpole, ALGENICS is a member of the competitiveness cluster ATLANTIC BIOTHERAPIES and the BLUE CLUSTER, the leading French marine bioresources hub.

Contact: Morgan Cabigliera, CEO
Email: contact(at)algenics(dot)com
Web: http://www.algenics.com

About the Roquette Group:

Founded in 1933 in Lestrem (Nord-Pas de Calais, France), the ROQUETTE Group is one of the world's leading starch producers. It converts renewable natural resources (such as wheat, corn, potatoes and peas) into a range of ingredients for the food processing, chemicals and pharmaceuticals industries. Reliability, expertise, innovation, anticipating needs and supporting its customers lie at the heart of ROQUETTE's products and services. Keen to build on its leadership position while continuing to innovate and diversify, this family-run business has made nutrition one of its key areas of development, expressed in tangible terms through an ambitious, dedicated research programme, NUTRAHUB®. The aim of this programme is to generate value from functional ingredients derived from plant raw materials, in particular microalgae. Microalgae offer high potential in Nutrition and Health and the ROQUETTE Group runs a dedicated programme, ALGOHUB®, for research in this area.

Contact: Philippe Caillat, NUTRAHUB® Marketing & Business Development Manager
Email: philippe(dot)caillat(at)roquette(dot)com
Web: http://www.algohub-roquette.com; http://www.roquette.com

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Visit website